ICU Medical, Inc. (ICUI)
Healthcare · NMS · US
Price as at 2 Oct 2026, 00:53 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
ICU Medical, Inc. trades at $157.18, which is 45% above the $86.05 our fair value estimate puts on the business. On that measure it screens as expensive, which is not the same as saying it will fall.
Our moat model scores it 31 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
It changes hands at 137.3 times earnings. Be careful reading that in isolation: for a cyclical business a low P/E arrives at the top of the cycle, when profits are peaking and about to fall, which is exactly when the shares look cheapest and are not.
ICUI earnings and analyst estimates
Recommendation mix, 8 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About ICU Medical, Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications worldwide. It offers Clave needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoLock closed system transfer devices and ChemoClaveTM for preparation and administration of hazardous drugs; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; ClearGuard, SwabCap, and SwabTip disinfection caps; and vascular access products. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride, sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
ICUI passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
9 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$78.61M · 0.0% of book
- Steve Cohen, Point72 Asset Management, L.P.$24.26M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$6.48M · 0.0% of book
- Marshall Wace, MARSHALL WACE, LLP$6.27M · 0.0% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$4.15M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in ICUI
We hold 8 disclosed trades in ICUI by members of Congress and executive-branch officials. The latest 5:
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 6 May 2025 · disclosed 6 Jun 2025
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 23 Dec 2020 · disclosed 11 Jan 2021
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 25 Sept 2020 · disclosed 14 Oct 2020
- Gilbert Cisneros · HouseBuy · $15,001 - $50,000 · traded 24 Sept 2020 · disclosed 14 Oct 2020
- Gilbert Cisneros · HouseBuy · $1,001 - $15,000 · traded 23 Sept 2020 · disclosed 14 Oct 2020
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
ICUI peers
The largest companies in the same industry (Medical Instruments & Supplies), then in the same sector.
- MDLN Medline Inc.
- RSMDF ResMed Inc.
- SRT3.DE Sartorius Aktiengesellschaft
- SOLV Solventum Corporation
- BAX Baxter International Inc.
- RGEN Repligen Corporation
- AVTR Avantor, Inc.
- TFX Teleflex Incorporated
Every healthcare company we cover is on the Healthcare hub.
Common questions
Is ICU Medical, Inc. (ICUI) undervalued?
Against our fair value estimate of $86.05, ICUI at $157.18 is 45% above fair value. That is one model's answer, not a recommendation. It is built from normalized earning power with growth capped deliberately low, which understates companies whose value is mostly future growth.
Which funds own ICUI?
9 of the institutions we track reported a position in ICUI in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
What is ICUI's P/E ratio?
ICUI trades at 137.3 times earnings. A low P/E is not automatically cheap: on a cyclical company it is usually a warning that earnings are at a peak.
When does ICUI report earnings next?
ICU Medical, Inc. is scheduled to report on 5 Nov 2026. Companies move earnings dates, so read it as scheduled rather than certain.
Where does SteadyShares get its ICUI data?
Fundamentals for ICUI come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 2 Oct 2026, 00:53 UTC and is delayed. Our data quality score for this company is 96/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ICUI, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.